Shana Kay Phares

56 year

Health Technology

Consumer Services

Profile

Shana Kay Phares served as the President & Chief Executive Officer at Blanchette Rockefeller Neurosciences Institute from 2010 to 2016.
She then worked as a Director at Neurotrope, Inc. from 2016 to 2020.
Prior to her career in neuroscience, she earned an undergraduate degree from Harvard University and an MBA from West Virginia University.

Former positions of Shana Kay Phares

Companies	Position	End
NEUROTROPE, INC.	Director/Board Member	2020-02-24
Blanchette Rockefeller Neurosciences Institute Blanchette Rockefeller Neurosciences Institute BiotechnologyHealth Technology Blanchette Rockefeller Neurosciences Institute provides health care solutions. The company offers to facilitate molecular signaling, which controls the functions that record our conscience experience. The company is headquartered in Morgantown, WV.	Chief Executive Officer	2015-12-31

See the detail of Shana Kay Phares's experience

Training of Shana Kay Phares

West Virginia University	Masters Business Admin
Harvard University	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Shana Kay Phares's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Blanchette Rockefeller Neurosciences Institute Blanchette Rockefeller Neurosciences Institute BiotechnologyHealth Technology Blanchette Rockefeller Neurosciences Institute provides health care solutions. The company offers to facilitate molecular signaling, which controls the functions that record our conscience experience. The company is headquartered in Morgantown, WV.	Health Technology
Neurotrope, Inc. Neurotrope, Inc. Pharmaceuticals: MajorHealth Technology Neurotrope, Inc. is a biopharmaceutical company, which engages in the pre-clinical and clinical development of its product candidates. The company focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C. The company was founded on January 11, 2011 and is headquartered in New York, NY.	Health Technology